Loading clinical trials...
Loading clinical trials...
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.
Conditions
Interventions
HQP1351
Locations
6
China
Sun-Yat Sen University Cancer Center
Guangzhou, Guangdong, China
Guangdong general hospital
Guangzhou, Guangdong, China
Henan cancer hospital
Zhengzhou, Henan, China
Union Hospital Tongji Medical College of Huazhong University of Science ang Technology
Wuhan, Hubei, China
Chinese PLA general hospital, Beijing, China
Beijing, China
Fudan University Shanghai Cancer Center
Shanghai, China
Start Date
July 11, 2018
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2028
Last Updated
April 9, 2026
NCT05223608
NCT06625775
NCT06051695
NCT06655246
NCT06265727
NCT04665206
Lead Sponsor
Ascentage Pharma Group Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions